Atropine Sources Sought Notice

Sources Sought Notice for ATROPINE INJECTION, Automatic, 2 mg Atropine Sulfate per 0.7 mL NSN: 6505-31-017-0350
Item Identification: ATROPINE INJECTION, Automatic, 2 mg Atropine Sulfate per 0.7 mL Medical Procurement Item Description: MPID #2 dated 13 May 2025 The Defense Logistics Agency Troop Support is seeking sources capable of providing the Atropine Injection, Automatic, 2mg Atropine Sulfate per 0.7mL. The subject item is a consumable Atropine autoinjector for treatment of muscarinic effects of the cholinergic crisis caused by nerve agents. The Atropine Autoinjector is a cholinergic muscarinic antagonist FDA approved for the initial treatment of muscarinic symptoms of known or suspected poisoning in individuals exposed to nerve agents or certain insecticides (organophosphorus and/or carbamate). Atropine is indicated for the treatment of poisoning and susceptible organophosphorus nerve agents having cholinesterase activity.

*************************************************************************************************************

DISCLAIMER:

Data obtained from this Sources Sought Notice/Request For Information (RFI) will be used by DLA Troop Support in making recommendations and decisions on the development of an appropriate planning and procurement strategy for the subject item. All information submitted shall remain with the U.S. Government and will not be returned. It will be kept confidential as allowed by relevant Federal law and will be eligible for additional special protections under the conditions of the Protected Critical Infrastructure Information (PCII) Program outlined in the Critical Infrastructure Information Act of 2002.

This Sources Sought Notice/RFI does not commit the U.S. Government to issue a solicitation, make an award, or pay any costs associated with responding to this announcement. *************************************************************************************************************

GOVERNMENT REQUIREMENT:

DLA Troop Support is contemplating awarding a firm-fixed price, indefinite delivery, indefinite quantity type contract with a one-year base term and four one-year option terms. Atropine Injection, Automatic, 2mg Atropine Sulfate per 0.7mL shall meet the individual requirements for the drug solution as set forth in the NDA. The volume range of the solution shall be 10MG/0.7 per mL. The delivered volume shall be the total drug delivered during the injection process. Shall be suitable for intramuscular administration. The formula shall meet the minimum formula for Atropine Injection as determined by the FDA and Related Biological Products Advisory Committee. The Atropine autoinjector shall be licensed by the Food and Drug Administration (FDA).